ID   SupB15RT
AC   CVCL_DR65
DR   PRIDE; PXD000394
DR   Wikidata; Q54970907
RX   PubMed=25576301;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C68659; Childhood B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2) BCR-ABL1
DI   ORDO; Orphanet_585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0103 ! SUP-B15
SX   Male
AG   9Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 29-06-23; Version: 10
//
RX   PubMed=25576301; DOI=10.1074/mcp.M114.042812;
RA   Bassani-Sternberg M., Pletscher-Frankild S., Jensen L.J., Mann M.;
RT   "Mass spectrometry of human leukocyte antigen class I peptidomes
RT   reveals strong effects of protein abundance and turnover on antigen
RT   presentation.";
RL   Mol. Cell. Proteomics 14:658-673(2015).
//